Evidence map›Paper›PMID 35593989›Full record

ArticleHuman cell2022

The α5-nAChR/PD-L1 axis facilitates lung adenocarcinoma cell migration and invasion.

Ping Zhu, Guiyu Kang, Yang Jiao, Chengzhi Gui, Huiping Fan, Xiangying Li, Yanfei Jia, Lulu Zhang, Xiaoli Ma

Abstract read
PubMed Publisher
In one paragraph

Article in Human cell, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Ping ZhuDepartment of Medical Laboratory, Weifang Medical University, Weifang, 261053, China.
Guiyu KangDepartment of Medical Laboratory, Weifang Medical University, Weifang, 261053, China.
Yang JiaoJinan Central Hospital, Shandong University, Jinan, 250013, China.
Chengzhi GuiResearch Center of Basic Medicine, Central Hospital Affiliated to Shandong First Medical University, Jinan, 250013, China.
Huiping FanResearch Center of Basic Medicine, Central Hospital Affiliated to Shandong First Medical University, Jinan, 250013, China.
Xiangying LiJinan Central Hospital, Shandong University, Jinan, 250013, China.
Yanfei JiaResearch Center of Basic Medicine, Central Hospital Affiliated to Shandong First Medical University, Jinan, 250013, China.
Lulu ZhangResearch Center of Basic Medicine, Central Hospital Affiliated to Shandong First Medical University, Jinan, 250013, China.
Xiaoli MaDepartment of Medical Laboratory, Weifang Medical University, Weifang, 261053, China. Maxiaoli_jn@sdu.edu.cn.ORCID http://orcid.org/0000-0003-0279-8354
Jinan Central Hospital · CNWeifang Medical University · CNShandong University · CN

Funding

National Natural Science Foundation of China 31970728Natural Science Foundation of Shandong Province ZR2018MH021Natural Science Foundation of Shandong Province ZR2021MH322
6 · The paper itself

Abstract

α5 nicotinic acetylcholine receptor (α5-nAChR) is associated with the progression of smoking-related lung adenocarcinoma (LUAD), but the molecular mechanism is unclear. Programmed death ligand 1 (PD-L1) is encoded by the CD274 gene, which not only inhibits the immune system, but also plays a unique role in tumor growth and metastasis. Here, we gained important insights into the underlying mechanism between α5-nAChR and PD-L1 in LUAD progression. α5-nAChR was overexpressed in various histological subtypes, cancer stages and metastasis statuses of LUAD. The group that coexpressed α5-nAChR and PD-L1 had a worse prognosis than the other subgroups at different stages of LUAD lymph node metastasis. The expression of α5-nAChR and PD-L1 was associated with epithelial-mesenchymal transition (EMT) marker CDH2. In vitro, α5-nAChR mediated nicotine-induced PD-L1 expression via STAT3 and the expression of EMT markers. Downregulation of α5-nAChR and/or PD-L1 inhibited EMT marker expression, cell proliferation, migration and invasion compared to silencing α5-nAChR or PD-L1 alone in LUAD cells. Furthermore, α5-nAChR expression was associated with PD-L1 and EMT marker expression in mouse xenograft models. These results highlight that α5-nAChR mediates STAT3/PD-L1 signaling, which contributes to cell migration and invasion. Therefore, our study may reveal a new interaction between α5-nAChR and PD-L1 that is involved in tumor cell growth and progression in LUAD, which may be a promising target for NSCLC diagnosis and immunotherapy.

Indexed as

Adenocarcinoma of LungCarcinoma, Non-Small-Cell LungLung NeoplasmsAnimalsB7-H1 AntigenCell Line, TumorCell MovementEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticHumansMiceB7-H1 AntigenEpithelial–mesenchymal transitionLung adenocarcinomaPD-L1STAT3α5 nicotinic acetylcholine receptor

Identifiers

PMID35593989
OpenAlexW4280501053

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.